Spyre Therapeutics, Inc. SYRE Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed August 7, 2024, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s enterprise value?
- Spyre Therapeutics, Inc. (SYRE) reported enterprise value of -$189.23M in Q2 2023.
- How has Spyre Therapeutics, Inc.'s enterprise value changed year-over-year?
- Spyre Therapeutics, Inc.'s enterprise value decreased by 1369.0% year-over-year, from $14.91M to -$189.23M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s enterprise value?
- Over 2 years (2020 to 2022), Spyre Therapeutics, Inc.'s enterprise value has grown at a -91.6% compound annual growth rate (CAGR), from $335.46M to -$2.36M.
- What does enterprise value mean?
- What it would cost to buy the entire business, debt included and cash netted out.
- How do you interpret enterprise value?
- The capital-structure-neutral valuation base — used in EV/EBITDA and EV/Sales to compare companies with different leverage on a like-for-like footing.
- How does enterprise value compare across companies?
- Comparable across non-financial companies via the EV multiples it feeds; not used for banks and insurers.